Hudson Bay Capital Management LP Has $4.45 Million Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Hudson Bay Capital Management LP grew its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 150.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 225,000 shares of the company's stock after buying an additional 135,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.31% of Kiniksa Pharmaceuticals worth $4,450,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Braidwell LP boosted its stake in Kiniksa Pharmaceuticals by 19.3% during the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the period. Geode Capital Management LLC boosted its position in shares of Kiniksa Pharmaceuticals by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company's stock worth $9,744,000 after purchasing an additional 9,654 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Kiniksa Pharmaceuticals by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares during the period. Finally, Northern Trust Corp increased its position in Kiniksa Pharmaceuticals by 11.1% in the 4th quarter. Northern Trust Corp now owns 283,599 shares of the company's stock valued at $5,610,000 after buying an additional 28,393 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of several recent research reports. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Finally, Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals Stock Up 3.1%

KNSA stock opened at $26.84 on Tuesday. The firm has a market capitalization of $1.95 billion, a PE ratio of -191.70 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $28.56. The stock's 50 day moving average is $22.51 and its 200-day moving average is $21.29.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. During the same period last year, the business earned ($0.25) EPS. The business's revenue was up 72.5% on a year-over-year basis. On average, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, insider Ross Moat sold 64,035 shares of the company's stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $25.21, for a total value of $1,614,322.35. Following the completion of the transaction, the insider now directly owns 9,415 shares of the company's stock, valued at $237,352.15. This represents a 87.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Michael R. Megna sold 17,647 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were sold at an average price of $26.69, for a total value of $470,998.43. Following the sale, the chief accounting officer now directly owns 32,546 shares of the company's stock, valued at $868,652.74. The trade was a 35.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 228,768 shares of company stock valued at $5,591,506 over the last ninety days. Corporate insiders own 54.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.